X0508 4 2023-07-20 0001635088 Roivant Sciences Ltd. ROIV 0001801917 Venker Eric C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true President & COO false Common Shares 2023-07-20 4 M 0 159387 3.85 A 803602 D Common Shares 2023-07-20 4 S 0 159387 11.31 D 644215 D Common Shares 2023-07-21 4 M 0 181998 3.85 A 826213 D Common Shares 2023-07-21 4 S 0 181998 11.13 D 644215 D Common Shares 2023-07-24 4 M 0 33081 3.85 A 677296 D Common Shares 2023-07-24 4 S 0 33081 10.93 D 644215 D Common Shares 2023-07-24 4 J 0 16297 10.99 D 627918 D Stock Option (Right to Buy) 3.85 2023-07-20 4 M 0 159387 0 D 2032-04-19 Common Shares 159387 15163797 D Stock Option (Right to Buy) 3.85 2023-07-21 4 M 0 181998 0 D 2032-04-19 Common Shares 181998 14981799 D Stock Option (Right to Buy) 3.85 2023-07-24 4 M 0 33081 0 D 2032-04-19 Common Shares 33081 14948718 D These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. These sales was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 2023-07-24